Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.

Pemmaraju N, Harrison C, Gupta V, Verstovsek S, Scott B, Oh ST, Palandri F, Al-Ali HK, Sobas M, McMullin MF, Mesa R, Buckley S, Roman-Torres K, Vannucchi A, Yacoub A

Open source

DOI: 10.1002/jha2.591
Published: 2022 Nov
Container: EJHaem
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/jha2.591,
  title = {Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.},
  author = {Pemmaraju N and Harrison C and Gupta V and Verstovsek S and Scott B and Oh ST and Palandri F and Al-Ali HK and Sobas M and McMullin MF and Mesa R and Buckley S and Roman-Torres K and Vannucchi A and Yacoub A},
  year = {2022},
  journal = {EJHaem},
  doi = {10.1002/jha2.591},
  url = {https://doi.org/10.1002/jha2.591}
}

RIS

TY  - JOUR
TI  - Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.
AU  - Pemmaraju N
AU  - Harrison C
AU  - Gupta V
AU  - Verstovsek S
AU  - Scott B
AU  - Oh ST
AU  - Palandri F
AU  - Al-Ali HK
AU  - Sobas M
AU  - McMullin MF
AU  - Mesa R
AU  - Buckley S
AU  - Roman-Torres K
AU  - Vannucchi A
AU  - Yacoub A
PY  - 2022
JO  - EJHaem
DO  - 10.1002/jha2.591
UR  - https://doi.org/10.1002/jha2.591
ER  -

APA

N, P., C, H., V, G., S, V., B, S., ST, O., F, P., HK, A., M, S., MF, M., R, M., S, B., K, R., A, V., & A, Y. (2022). Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.. EJHaem. https://doi.org/10.1002/jha2.591

Source records

pubmed · retrieved 2026-09-26T19:04:50.446Z